Metric Finance
LearnFAQ
LearnFAQ

Learn / EYE

NASDAQ: EYE

National Vision Holdings (EYE) stock, explained like you're 5

National Vision Holdings trades on the Nasdaq under the ticker EYE. It is a small cap company in the ophthalmic goods industry, part of the healthcare sector, with a market value of about 1.3 billion dollars.

Ticker
EYE
Exchange
Nasdaq
Sector
Healthcare
Industry
Ophthalmic Goods
Size
Small cap, about 1.3 billion dollars

Is National Vision Holdings a small, medium or large cap company?

No. National Vision Holdings is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 1.3 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How National Vision Holdings makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves EYE stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • 1 Cash Heavy Stock to Keep an Eye On and 2 We Question (Yahoo Finance)
  • 2 of Wall Street’s Favorite Stocks to Keep an Eye On and 1 Facing Challenges (StockStory)
  • Optometry students can apply for $12,500 in scholarships. Entries close Jan. 31, 2027. (Stock Titan)
  • Micron Stock Has Some Eye Popping Analyst Targets. Here’s My Price Prediction (24/7 Wall St.)
  • Glencore shares trade higher on ASX debut as investors eye copper (Reuters)

Follow EYE in your daily brief

Each trading day at 5 PM ET we post what happened to National Vision Holdings and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow EYE

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about National Vision Holdings stock

What does National Vision Holdings do?

National Vision Holdings trades on the Nasdaq under the ticker EYE. It is a small cap company in the ophthalmic goods industry, part of the healthcare sector, with a market value of about 1.3 billion dollars.

What is the ticker symbol for National Vision Holdings?

National Vision Holdings trades under the ticker EYE on the Nasdaq.

What is National Vision Holdings's market cap?

National Vision Holdings is a small cap stock with a market cap of about 1.3 billion dollars.

How does National Vision Holdings make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves EYE stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow EYE stock every day?

Add EYE to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow EYE daily

A free brief on National Vision Holdings and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • ALC · Alcon
  • COO · Cooper Companies
  • BLCO · Bausch & Lomb
  • WRBY · Warby Parker

Similar stocks

  • ALCAlcon
  • COOCooper Companies
  • BLCOBausch & Lomb
  • WRBYWarby Parker

Compare EYE: EYE vs ALC, EYE vs COO, EYE vs BLCO

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed